A Research Study of VCT220 in Adult Chinese Participants With Obesity

Inclusion Criteria:

• Age 18-75 years, both male and female;

• At screening, BMI ≥ 28 kg/m² or 24 kg/m² ≤ BMI < 28 kg/m² with at least one of thefollowing conditions:

1. Comorbid prediabetes (impaired fasting glucose and/or abnormal glucosetolerance), hypertension, dyslipidemia, or fatty liver (within the past 6months prior to screening);

2. Comorbid weight-bearing joint pain (as determined by the investigator,excluding joint pain caused by other diseases);

3. Obesity-related shortness of breath or obstructive sleep apnea syndrome;

• Weight change during the past 3 months due to diet and exercise control should notexceed 5% (self-reported); weight change calculation formula: (highest weight -lowest weight in the past 3 months) / highest weight * 100%;

• Willing and able to maintain a stable diet and exercise regimen throughout thestudy;

• Fully understands the purpose of the study, able to communicate well with theinvestigator, can comprehend and comply with the requirements of this study, and iswilling to sign the informed consent form

Exclusion Criteria:

• Patients with type 1, type 2, or other types of diabetes.

• A history of endocrine diseases or obesity caused by single gene mutations,including but not limited to hypothalamic obesity, pituitary obesity, hypothyroidobesity, Cushing's syndrome, insulinoma, acromegaly, and hypogonadism.

• A history of weight-loss surgery (except for liposuction performed more than 1 yearago) or plans to undergo weight-loss surgery, use weight-loss devices, or medicalequipment during the study.

• Has used any of the following medications or treatments:

1. Has previously used any GLP-1 receptor agonists (GLP-1RAs), GLP-1-relatedmulti-target agonists (such as GLP-1/glucose-dependent insulinotropic peptide [GIP] dual receptor agonists, GLP-1 receptor/glucagon receptor [GCGR] dualagonists, GLP-1/GIP/glucagon [GCG] triple receptor agonists, etc.), orcombination formulations containing GLP-1RAs (such as exenatide, liraglutide,semaglutide, benaglutide, etc.);

2. Within the past 6 months prior to screening, has used any approved orunapproved weight-loss medications other than GLP-1 receptor agonists (GLP-1RAs) and GLP-1-related multi-target agonists (such as orlistat,phentermine/topiramate, naltrexone/bupropion, etc.), or weight-affecting herbalmedicines, supplements, meal replacements, etc.;

3. Within the past 3 months prior to screening, has used any antidiabeticmedications, such as metformin, α-glucosidase inhibitors, sulfonylureas,dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, thiazolidinediones (TZDs), etc.;

4. Within the past 3 months prior to screening, has used any medications that maycause significant weight gain, including systemic corticosteroid treatment formore than 1 week, tricyclic antidepressants, antipsychotic or anticonvulsantmedications (e.g., imipramine, amitriptyline, mirtazapine, paroxetine,phenelzine, chlorpromazine, clozapine, olanzapine, valproic acid and itsderivatives, lithium salts, methyldopa, etc.).